Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow IKT
Inhibikase Therapeutics, Inc. (IKT) Altman Z-score
Inhibikase Therapeutics, Inc.'s Altman Z-score for fiscal 2023 is −8.82, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2023 | −8.82 | (6.68) |
| FY2022 | −2.14 | (5.13) |
| FY2021 | 2.99 | (2.62) |
| FY2020 | 5.62 | — |
How fiscal 2023’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.74 | — | 0.89 | |
| Retained earnings / total assets | (4.61) | — | −6.46 | |
| EBIT / total assets | (1.38) | — | −4.57 | |
| Market value of equity / total liabilities | 2.17 | — | 1.30 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −8.82 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −16.20 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| VNDA Vanda Pharmaceuticals Inc. compare | 0.7× |
| XFOR X4 Pharmaceuticals, Inc. compare | −1.8× |
| ABEO Abeona Therapeutics Inc. compare | −2.3× |
| LCTX Lineage Cell Therapeutics, Inc. compare | −2.9× |
| ACIU AC Immune compare | −4.0× |
| PRLD Prelude Therapeutics Incorporated compare | −6.8× |
| IKT Inhibikase Therapeutics, Inc. | −8.8× |
| CABA Cabaletta Bio, Inc. compare | — |
| RCKT Rocket Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets